Raymond James on WAVE Life Sciences (WVE): 'We continue to view WVE’s wholly-owned gene-editing programs as more likely LT value drivers'
Tweet Send to a Friend
Raymond James analyst Michael Freeman reiterated an Outperform rating and $14.00 price target on WAVE Life Sciences (NASDAQ: WVE).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
